A detailed history of Guggenheim Capital LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Guggenheim Capital LLC holds 278,527 shares of ABBV stock, worth $50.6 Million. This represents 0.39% of its overall portfolio holdings.

Number of Shares
278,527
Previous 297,509 6.38%
Holding current value
$50.6 Million
Previous $51 Million 7.79%
% of portfolio
0.39%
Previous 0.37%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$163.84 - $199.33 $3.11 Million - $3.78 Million
-18,982 Reduced 6.38%
278,527 $55 Million
Q2 2024

Aug 14, 2024

SELL
$154.79 - $180.76 $2.66 Million - $3.1 Million
-17,176 Reduced 5.46%
297,509 $51 Million
Q1 2024

May 14, 2024

BUY
$159.82 - $182.1 $2.59 Million - $2.95 Million
16,183 Added 5.42%
314,685 $57.3 Million
Q4 2023

Feb 14, 2024

SELL
$137.6 - $154.97 $7.4 Million - $8.34 Million
-53,797 Reduced 15.27%
298,502 $46.3 Million
Q3 2023

Nov 14, 2023

SELL
$133.59 - $154.65 $9.64 Million - $11.2 Million
-72,151 Reduced 17.0%
352,299 $52.5 Million
Q2 2023

Aug 11, 2023

SELL
$132.51 - $164.9 $5.26 Million - $6.55 Million
-39,714 Reduced 8.56%
424,450 $57.2 Million
Q1 2023

May 10, 2023

SELL
$144.61 - $166.54 $15 Million - $17.2 Million
-103,456 Reduced 18.23%
464,164 $74 Million
Q4 2022

Feb 14, 2023

SELL
$138.31 - $165.87 $10.9 Million - $13 Million
-78,473 Reduced 12.15%
567,620 $91.8 Million
Q3 2022

Nov 14, 2022

SELL
$134.21 - $153.93 $6.13 Million - $7.03 Million
-45,663 Reduced 6.6%
646,093 $86.7 Million
Q2 2022

Aug 15, 2022

SELL
$137.62 - $174.96 $16.5 Million - $21 Million
-120,223 Reduced 14.81%
691,756 $106 Million
Q1 2022

May 16, 2022

BUY
$131.98 - $163.75 $2.08 Million - $2.58 Million
15,730 Added 1.98%
811,979 $132 Million
Q4 2021

Feb 14, 2022

BUY
$107.43 - $135.93 $5.48 Million - $6.93 Million
51,017 Added 6.85%
796,249 $108 Million
Q3 2021

Nov 15, 2021

BUY
$106.4 - $120.78 $1.43 Million - $1.63 Million
13,472 Added 1.84%
745,232 $80.4 Million
Q2 2021

Aug 13, 2021

BUY
$105.21 - $117.21 $682,286 - $760,106
6,485 Added 0.89%
731,760 $82.4 Million
Q1 2021

May 13, 2021

SELL
$102.3 - $112.62 $911,390 - $1 Million
-8,909 Reduced 1.21%
725,275 $78.5 Million
Q4 2020

Feb 16, 2021

SELL
$80.49 - $108.67 $85,158 - $114,972
-1,058 Reduced 0.14%
734,184 $78.7 Million
Q3 2020

Nov 13, 2020

SELL
$85.91 - $100.83 $5.25 Million - $6.16 Million
-61,122 Reduced 7.68%
735,242 $64.4 Million
Q2 2020

Aug 14, 2020

BUY
$73.37 - $98.18 $7.47 Million - $9.99 Million
101,789 Added 14.65%
796,364 $78.2 Million
Q1 2020

Jun 02, 2020

SELL
$64.5 - $97.79 $2.6 Million - $3.93 Million
-40,234 Reduced 5.48%
694,575 $52.9 Million
Q4 2019

Feb 14, 2020

BUY
$72.13 - $90.25 $6.58 Million - $8.24 Million
91,269 Added 14.18%
734,809 $65.1 Million
Q3 2019

Nov 14, 2019

SELL
$62.98 - $75.72 $817,417 - $982,769
-12,979 Reduced 1.98%
643,540 $48.7 Million
Q2 2019

Aug 14, 2019

SELL
$65.7 - $83.98 $1.58 Million - $2.02 Million
-24,087 Reduced 3.54%
656,519 $47.7 Million
Q1 2019

May 15, 2019

BUY
$77.14 - $90.79 $6.69 Million - $7.87 Million
86,734 Added 14.6%
680,606 $54.9 Million
Q4 2018

Feb 14, 2019

SELL
$77.85 - $96.01 $9.66 Million - $11.9 Million
-124,066 Reduced 17.28%
593,872 $54.7 Million
Q3 2018

Nov 14, 2018

SELL
$88.91 - $98.84 $5.35 Million - $5.95 Million
-60,188 Reduced 7.73%
717,938 $67.9 Million
Q2 2018

Aug 14, 2018

SELL
$89.78 - $106.23 $63.9 Million - $75.6 Million
-711,508 Reduced 47.76%
778,126 $72.1 Million
Q1 2018

May 15, 2018

SELL
$92.01 - $123.21 $22.8 Million - $30.5 Million
-247,522 Reduced 14.25%
1,489,634 $141 Million
Q4 2017

Feb 14, 2018

BUY
$89.56 - $98.21 $8.54 Million - $9.36 Million
95,342 Added 5.81%
1,737,156 $168 Million
Q3 2017

Nov 14, 2017

BUY
$69.85 - $89.22 $115 Million - $146 Million
1,641,814
1,641,814 $146 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $321B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Guggenheim Capital LLC Portfolio

Follow Guggenheim Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Guggenheim Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Guggenheim Capital LLC with notifications on news.